239 related articles for article (PubMed ID: 31382663)
1. Specific and Non-Specific Biomarkers in Neuroendocrine Gastroenteropancreatic Tumors.
Sansone A; Lauretta R; Vottari S; Chiefari A; Barnabei A; Romanelli F; Appetecchia M
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31382663
[TBL] [Abstract][Full Text] [Related]
2. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs).
Kanakis G; Kaltsas G
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):791-802. PubMed ID: 23582919
[TBL] [Abstract][Full Text] [Related]
3. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
4. Gastroenteropancreatic endocrine tumors.
Meeker A; Heaphy C
Mol Cell Endocrinol; 2014 Apr; 386(1-2):101-20. PubMed ID: 23906538
[TBL] [Abstract][Full Text] [Related]
5. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
Johnson PR
Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
[TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers and molecular imaging in gastroenteropancreatic neuroendocrine tumors.
Lindholm DP; Oberg K
Horm Metab Res; 2011 Nov; 43(12):832-7. PubMed ID: 22009449
[TBL] [Abstract][Full Text] [Related]
8. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
[TBL] [Abstract][Full Text] [Related]
9. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
Chauhan A; Chan K; Halfdanarson TR; Bellizzi AM; Rindi G; O'Toole D; Ge PS; Jain D; Dasari A; Anaya DA; Bergsland E; Mittra E; Wei AC; Hope TA; Kendi AT; Thomas SM; Flem S; Brierley J; Asare EA; Washington K; Shi C
CA Cancer J Clin; 2024 Apr; ():. PubMed ID: 38685134
[TBL] [Abstract][Full Text] [Related]
10. The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours.
Foltyn W; Zajęcki W; Marek B; Kajdaniuk D; Siemińska L; Zemczak A; Kos-Kudła B
Endokrynol Pol; 2012; 63(5):362-6. PubMed ID: 23115069
[TBL] [Abstract][Full Text] [Related]
11. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).
Oberg K
Curr Opin Endocrinol Diabetes Obes; 2009 Feb; 16(1):72-8. PubMed ID: 19115524
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
13. Role of biomarker tests for diagnosis of neuroendocrine tumours.
Hofland J; Zandee WT; de Herder WW
Nat Rev Endocrinol; 2018 Nov; 14(11):656-669. PubMed ID: 30158549
[TBL] [Abstract][Full Text] [Related]
14. LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors.
Sampedro-Núñez M; Bouthelier A; Serrano-Somavilla A; Martínez-Hernández R; Adrados M; Martín-Pérez E; Muñoz de Nova JL; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Díaz JÁ; García-Centeno R; Aragones J; Marazuela M
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066332
[TBL] [Abstract][Full Text] [Related]
15. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
16. Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.
Kos-Kudła B; Ćwikła J; Ruchała M; Hubalewska-Dydejczyk A; Jarzab B; Krajewska J; Kamiński G
Contemp Oncol (Pozn); 2017; 21(2):115-122. PubMed ID: 28947880
[TBL] [Abstract][Full Text] [Related]
17. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing.
Panarelli N; Tyryshkin K; Wong JJM; Majewski A; Yang X; Scognamiglio T; Kim MK; Bogardus K; Tuschl T; Chen YT; Renwick N
Endocr Relat Cancer; 2019 Jan; 26(1):47-57. PubMed ID: 30021866
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous Metastasis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets).
Dhingra R; Tse JY; Saif MW
JOP; 2018 Sep; 19(5):. PubMed ID: 30405324
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Impact of Peptide Hormonal Expression in Rectal Neuroendocrine Tumors.
Kim J; Yang DH; Jung H; Cho H; Jang HJ; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Arch Pathol Lab Med; 2023 Jul; 147(7):797-807. PubMed ID: 36191342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
